JPMorgan Chase & Co’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.7M | Buy |
140,610
+112,637
| +403% | +$4.56M | ﹤0.01% | 2597 |
|
|
2025
Q1 | $1.44M | Sell |
27,973
-101,211
| -78% | -$5.2M | ﹤0.01% | 3454 |
|
|
2024
Q4 | $7.15M | Sell |
129,184
-310,983
| -71% | -$17.2M | ﹤0.01% | 2499 |
|
|
2024
Q3 | $14.5M | Buy |
440,167
+420,057
| +2,089% | +$13.8M | ﹤0.01% | 1925 |
|
|
2024
Q2 | $547K | Sell |
20,110
-33,229
| -62% | -$903K | ﹤0.01% | 3818 |
|
|
2024
Q1 | $1.94M | Buy |
53,339
+27,769
| +109% | +$1.01M | ﹤0.01% | 3176 |
|
|
2023
Q4 | $518K | Buy |
25,570
+3,468
| +16% | +$70.2K | ﹤0.01% | 3890 |
|
|
2023
Q3 | $393K | Buy |
22,102
+2,903
| +15% | +$51.6K | ﹤0.01% | 3851 |
|
|
2023
Q2 | $347K | Buy |
19,199
+4,230
| +28% | +$76.4K | ﹤0.01% | 3961 |
|
|
2023
Q1 | $188K | Buy |
14,969
+3,618
| +32% | +$45.4K | ﹤0.01% | 4360 |
|
|
2022
Q4 | $167K | Buy |
11,351
+1,309
| +13% | +$19.3K | ﹤0.01% | 4282 |
|
|
2022
Q3 | $172K | Buy |
10,042
+349
| +4% | +$5.98K | ﹤0.01% | 4234 |
|
|
2022
Q2 | $142K | Buy |
9,693
+5,739
| +145% | +$84.1K | ﹤0.01% | 4474 |
|
|
2022
Q1 | $67K | Sell |
3,954
-170,782
| -98% | -$2.89M | ﹤0.01% | 4905 |
|
|
2021
Q4 | $3.93M | Buy |
174,736
+171,499
| +5,298% | +$3.86M | ﹤0.01% | 2743 |
|
|
2021
Q3 | $70K | Sell |
3,237
-1,925
| -37% | -$41.6K | ﹤0.01% | 4857 |
|
|
2021
Q2 | $150K | Sell |
5,162
-5,750
| -53% | -$167K | ﹤0.01% | 4616 |
|
|
2021
Q1 | $352K | Sell |
10,912
-5,871
| -35% | -$189K | ﹤0.01% | 4218 |
|
|
2020
Q4 | $694K | Buy |
+16,783
| New | +$694K | ﹤0.01% | 3577 |
|